Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sintilimab in Locally Advanced Head and Neck Squamous Cell Carcinoma: NCT07781072 Clinical Landscape Report 2026
18 September 2026
NCT07781072 clinical landscape for Locally Advanced Head and Neck Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Vitamin E/Ascorbic Acid in Neuroinflammation: NCT07782411 Clinical Landscape Report 2026
18 September 2026
NCT07782411 clinical landscape for Neuroinflammation: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Boswellia serrata extract in Radiodermatitis: NCT07778290 Clinical Landscape Report 2026
18 September 2026
NCT07778290 clinical landscape for Radiodermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Obesity: NCT07783854 Clinical Landscape Report 2026
18 September 2026
NCT07783854 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
8 min read
HX-044 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
HX-044: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
XMVA-09 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
XMVA-09: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
ANOC-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
ANOC-002: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PNB-028 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PNB-028: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
INB-410 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
INB-410: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
BMS-986523 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
BMS-986523: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EB-DT-CAR-NK(CLDN18.2/HER2) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
EB-DT-CAR-NK(CLDN18.2/HER2): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
161Tb-NYM032 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
161Tb-NYM032: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position.